MedTrace Logo

Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia

NCT00306319 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-11-12

No results posted yet for this study

Summary

Pharmacokinetic study in TB patients to determine the effect of rifampicin on the pharmacokinetic profile of moxifloxacin.

Conditions

Interventions

DRUG

moxifloxacin

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • R. Aarnoutse, PharmD PhD · Radboud University (RUNMC)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2006-05-31
Completion
2006-05-31

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00306319 on ClinicalTrials.gov